Jeremy Bender
Chief Executive Officer at DAY ONE BIOPHARMACEUTICALS, INC.
Net worth: 23 M $ as of 30/05/2024
Profile
Jeremy Bender is currently the Chief Executive Officer at DOT Therapeutics-2, Inc., the President, Chief Executive Officer & Director at Day One Biopharmaceuticals, Inc., and the Non-Executive Director at Mereo BioPharma Group Plc.
Previously, he held positions as the Director at Fusion Pharmaceuticals, Inc., Vice President-Corporate Development at Gilead Sciences, Inc., Vice President-Corporate Development at Allos Therapeutics, Inc., Chief Business Officer at Sutro Biopharma, Inc., Chief Operating Officer at Tizona Therapeutics, Inc., and Project Leader at The Boston Consulting Group, Inc. Dr. Bender obtained his undergraduate degree from Stanford University, his doctorate from The University of Colorado, and his MBA from MIT Sloan School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/05/2024 | 1,698,452 ( 1.94% ) | 23 M $ | 30/05/2024 | |
| 16/06/2024 | 62,750 ( 0.01% ) | 43 298 $ | 30/05/2024 |
Jeremy Bender active positions
| Companies | Position | Start |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Director/Board Member | 30/09/2020 |
| DAY ONE BIOPHARMACEUTICALS, INC. | Chief Executive Officer | 31/08/2020 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Former positions of Jeremy Bender
| Companies | Position | End |
|---|---|---|
| FUSN PHAR | Director/Board Member | 03/06/2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 31/08/2020 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Chief Operating Officer | 28/02/2018 |
| SUTRO BIOPHARMA, INC. | Corporate Officer/Principal | 30/06/2015 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 31/08/2012 |
Training of Jeremy Bender
| The University of Colorado | Doctorate Degree |
| Stanford University | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
- Stock Market
- Insiders
- Jeremy Bender
